Systemic neurotransplantation - A problem-oriented systematic review

Miroslaw Janowski, Isao Date

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Systemic neurotransplantation (SNT) was introduced in the laboratory in 2000 and currently it is being widely examined in animal models of neurological disorders. The aim of this systematic review was to evaluate the current state of knowledge in the field of experimental SNT and the premise for the introduction of clinical trials. PubMed was searched and 60 articles utilizing an SNT approach were found and subjected to analysis. The time window for cell transplantation was addressed in only two studies, with contradictory results. Immunosuppression was applied in 25% of studies. No study addressed the justification for immunosuppression. Bone marrow was the most frequent source of grafted cells, followed by cord blood and then by cells of embryonic origin. Studies investigating dose- dependency revealed no satisfactory results with transplantation of less than 10 6 cells/animal; the efficient dose most frequently ranged from 10 6- 10 7 cells/animal (mice and rats). The behavioral effects of cell transplantation were assessed in 75% of all studies; significant improvement was achieved in 95% of them. Morphological effect was evaluated in half of the studies; significant positive effect was achieved in 73% of them. Experimental attempts to elucidate the mecha-nisms mediating cell-dependent effect were not undertaken in half of the studies. In the other half, the most frequent mechanisms were growth factors, neurogenesis and immunomodulation. SNT still seems to be at the very initial stage of development. Many critical factors have not been sufficiently addressed in laboratory studies and they must be clarified before the introduction of clinical trials.

Original languageEnglish
Pages (from-to)39-60
Number of pages22
JournalReviews in the Neurosciences
Volume20
Issue number1
Publication statusPublished - 2009

Fingerprint

Cell Transplantation
Immunosuppression
Clinical Trials
Immunomodulation
Neurogenesis
Nervous System Diseases
Fetal Blood
PubMed
Blood Cells
Intercellular Signaling Peptides and Proteins
Animal Models
Transplantation
Bone Marrow

Keywords

  • Cell therapy
  • Intravenous
  • Neurological disorders
  • Neurotransplantation
  • Stem cells
  • Systemic

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Systemic neurotransplantation - A problem-oriented systematic review. / Janowski, Miroslaw; Date, Isao.

In: Reviews in the Neurosciences, Vol. 20, No. 1, 2009, p. 39-60.

Research output: Contribution to journalArticle

@article{82202bf07c33437ea8c38b4201e36720,
title = "Systemic neurotransplantation - A problem-oriented systematic review",
abstract = "Systemic neurotransplantation (SNT) was introduced in the laboratory in 2000 and currently it is being widely examined in animal models of neurological disorders. The aim of this systematic review was to evaluate the current state of knowledge in the field of experimental SNT and the premise for the introduction of clinical trials. PubMed was searched and 60 articles utilizing an SNT approach were found and subjected to analysis. The time window for cell transplantation was addressed in only two studies, with contradictory results. Immunosuppression was applied in 25{\%} of studies. No study addressed the justification for immunosuppression. Bone marrow was the most frequent source of grafted cells, followed by cord blood and then by cells of embryonic origin. Studies investigating dose- dependency revealed no satisfactory results with transplantation of less than 10 6 cells/animal; the efficient dose most frequently ranged from 10 6- 10 7 cells/animal (mice and rats). The behavioral effects of cell transplantation were assessed in 75{\%} of all studies; significant improvement was achieved in 95{\%} of them. Morphological effect was evaluated in half of the studies; significant positive effect was achieved in 73{\%} of them. Experimental attempts to elucidate the mecha-nisms mediating cell-dependent effect were not undertaken in half of the studies. In the other half, the most frequent mechanisms were growth factors, neurogenesis and immunomodulation. SNT still seems to be at the very initial stage of development. Many critical factors have not been sufficiently addressed in laboratory studies and they must be clarified before the introduction of clinical trials.",
keywords = "Cell therapy, Intravenous, Neurological disorders, Neurotransplantation, Stem cells, Systemic",
author = "Miroslaw Janowski and Isao Date",
year = "2009",
language = "English",
volume = "20",
pages = "39--60",
journal = "Reviews in the Neurosciences",
issn = "0334-1763",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "1",

}

TY - JOUR

T1 - Systemic neurotransplantation - A problem-oriented systematic review

AU - Janowski, Miroslaw

AU - Date, Isao

PY - 2009

Y1 - 2009

N2 - Systemic neurotransplantation (SNT) was introduced in the laboratory in 2000 and currently it is being widely examined in animal models of neurological disorders. The aim of this systematic review was to evaluate the current state of knowledge in the field of experimental SNT and the premise for the introduction of clinical trials. PubMed was searched and 60 articles utilizing an SNT approach were found and subjected to analysis. The time window for cell transplantation was addressed in only two studies, with contradictory results. Immunosuppression was applied in 25% of studies. No study addressed the justification for immunosuppression. Bone marrow was the most frequent source of grafted cells, followed by cord blood and then by cells of embryonic origin. Studies investigating dose- dependency revealed no satisfactory results with transplantation of less than 10 6 cells/animal; the efficient dose most frequently ranged from 10 6- 10 7 cells/animal (mice and rats). The behavioral effects of cell transplantation were assessed in 75% of all studies; significant improvement was achieved in 95% of them. Morphological effect was evaluated in half of the studies; significant positive effect was achieved in 73% of them. Experimental attempts to elucidate the mecha-nisms mediating cell-dependent effect were not undertaken in half of the studies. In the other half, the most frequent mechanisms were growth factors, neurogenesis and immunomodulation. SNT still seems to be at the very initial stage of development. Many critical factors have not been sufficiently addressed in laboratory studies and they must be clarified before the introduction of clinical trials.

AB - Systemic neurotransplantation (SNT) was introduced in the laboratory in 2000 and currently it is being widely examined in animal models of neurological disorders. The aim of this systematic review was to evaluate the current state of knowledge in the field of experimental SNT and the premise for the introduction of clinical trials. PubMed was searched and 60 articles utilizing an SNT approach were found and subjected to analysis. The time window for cell transplantation was addressed in only two studies, with contradictory results. Immunosuppression was applied in 25% of studies. No study addressed the justification for immunosuppression. Bone marrow was the most frequent source of grafted cells, followed by cord blood and then by cells of embryonic origin. Studies investigating dose- dependency revealed no satisfactory results with transplantation of less than 10 6 cells/animal; the efficient dose most frequently ranged from 10 6- 10 7 cells/animal (mice and rats). The behavioral effects of cell transplantation were assessed in 75% of all studies; significant improvement was achieved in 95% of them. Morphological effect was evaluated in half of the studies; significant positive effect was achieved in 73% of them. Experimental attempts to elucidate the mecha-nisms mediating cell-dependent effect were not undertaken in half of the studies. In the other half, the most frequent mechanisms were growth factors, neurogenesis and immunomodulation. SNT still seems to be at the very initial stage of development. Many critical factors have not been sufficiently addressed in laboratory studies and they must be clarified before the introduction of clinical trials.

KW - Cell therapy

KW - Intravenous

KW - Neurological disorders

KW - Neurotransplantation

KW - Stem cells

KW - Systemic

UR - http://www.scopus.com/inward/record.url?scp=67049132435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67049132435&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 39

EP - 60

JO - Reviews in the Neurosciences

JF - Reviews in the Neurosciences

SN - 0334-1763

IS - 1

ER -